ING Groep NV Acquires 699,851 Shares of Catalent, Inc. (NYSE:CTLT)

ING Groep NV boosted its holdings in Catalent, Inc. (NYSE:CTLT - Free Report) by 162.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,130,504 shares of the company's stock after purchasing an additional 699,851 shares during the period. ING Groep NV owned approximately 0.62% of Catalent worth $68,475,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in CTLT. Metis Global Partners LLC increased its position in shares of Catalent by 5.3% in the third quarter. Metis Global Partners LLC now owns 8,294 shares of the company's stock valued at $502,000 after acquiring an additional 417 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Catalent by 3.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company's stock valued at $24,550,000 after acquiring an additional 14,373 shares during the period. OVERSEA CHINESE BANKING Corp Ltd increased its position in shares of Catalent by 18.8% in the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 6,242 shares of the company's stock valued at $378,000 after acquiring an additional 988 shares during the period. Wolverine Asset Management LLC increased its position in shares of Catalent by 9.1% in the third quarter. Wolverine Asset Management LLC now owns 46,685 shares of the company's stock valued at $2,828,000 after acquiring an additional 3,908 shares during the period. Finally, Crossmark Global Holdings Inc. increased its position in shares of Catalent by 2.6% during the third quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company's stock valued at $553,000 after buying an additional 229 shares during the period.

Catalent Stock Down 0.3 %

CTLT traded down $0.20 during midday trading on Thursday, reaching $58.95. The company's stock had a trading volume of 1,122,589 shares, compared to its average volume of 2,037,328. The firm has a market capitalization of $10.70 billion, a price-to-earnings ratio of -26.07, a PEG ratio of 2.36 and a beta of 1.16. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. Catalent, Inc. has a 1 year low of $36.00 and a 1 year high of $61.20. The stock's 50-day moving average is $59.89 and its 200-day moving average is $58.16.

Catalent (NYSE:CTLT - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.10) EPS. As a group, research analysts expect that Catalent, Inc. will post 0.84 EPS for the current year.

Insider Transactions at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,114 shares of company stock worth $305,931. Corporate insiders own 0.31% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. StockNews.com upgraded shares of Catalent from a "sell" rating to a "hold" rating in a research report on Thursday. Baird R W cut shares of Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. William Blair reiterated a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Robert W. Baird reiterated a "neutral" rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Nine research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $59.83.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.